Healthcare provider profile · identity verified

Jonathan Daniel Dee, MD

Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1346335957

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jonathan Daniel Dee, MD received $51.55 in general payments during 2025 across 1 reported records.

HEARTFLOW, INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$51.55

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
HEARTFLOW, INC. Unresolved — no canonical attribution shown $51.55100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$51.551

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
FFRct
Normalized: ffrct
Device HEARTFLOW, INC. $51.55 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium20062
Levothyroxine SodiumLevothyroxine Sodium16345
Rosuvastatin CalciumRosuvastatin Calcium12441
LisinoprilLisinopril10630
Pantoprazole SodiumPantoprazole Sodium9930
Losartan PotassiumLosartan Potassium9731
Amlodipine BesylateAmlodipine Besylate9131
Alendronate SodiumAlendronate Sodium8221
Tamsulosin HclTamsulosin Hcl7928
OmeprazoleOmeprazole7724
AlprazolamAlprazolam7415
SimvastatinSimvastatin6620
GabapentinGabapentin6418
FinasterideFinasteride6219
Trazodone HclTrazodone Hcl6221
MeloxicamMeloxicam6119
Montelukast SodiumMontelukast Sodium6025
CarvedilolCarvedilol5615
Zolpidem TartrateZolpidem Tartrate5511
ValsartanValsartan5223
Metformin Hcl ErMetformin Hcl5117
Duloxetine HclDuloxetine Hcl5015
EliquisApixaban5014
Pravastatin SodiumPravastatin Sodium4714
Escitalopram OxalateEscitalopram Oxalate4617
Benazepril HclBenazepril Hcl4513
Metoprolol SuccinateMetoprolol Succinate4313
Albuterol Sulfate HfaAlbuterol Sulfate4111
Metformin HclMetformin Hcl4113
LovastatinLovastatin40suppressed
Bupropion XlBupropion Hcl3915
HydrochlorothiazideHydrochlorothiazide3915
Pioglitazone HclPioglitazone Hcl3911
FamotidineFamotidine3711
Sertraline HclSertraline Hcl3411
LorazepamLorazepam33suppressed
ValacyclovirValacyclovir Hcl3315
Diltiazem 24hr Er (Cd)Diltiazem Hcl32suppressed
PrednisonePrednisone3220
Fluticasone PropionateFluticasone Propionate3111
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31suppressed
AllopurinolAllopurinol29suppressed
AtenololAtenolol29suppressed
Hydralazine HclHydralazine Hcl27suppressed
Metoprolol TartrateMetoprolol Tartrate2712
TemazepamTemazepam27suppressed
Olmesartan MedoxomilOlmesartan Medoxomil26suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid26suppressed
IrbesartanIrbesartan25suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide24suppressed
Fluoxetine HclFluoxetine Hcl22suppressed
TopiramateTopiramate22suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril21suppressed
FluconazoleFluconazole2118
FurosemideFurosemide21suppressed
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21suppressed
Venlafaxine Hcl ErVenlafaxine Hcl21suppressed
Warfarin SodiumWarfarin Sodium20suppressed
ChlorthalidoneChlorthalidone18suppressed
Ciprofloxacin HclCiprofloxacin Hcl1817
ClopidogrelClopidogrel Bisulfate18suppressed
DiazepamDiazepam18suppressed
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide18suppressed
EstradiolEstradiol17suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide17suppressed
SynthroidLevothyroxine Sodium17suppressed
Citalopram HbrCitalopram Hydrobromide16suppressed
Azelastine HclAzelastine Hcl15suppressed
CefdinirCefdinir1515
CelecoxibCelecoxib15suppressed
JanuviaSitagliptin Phosphate15suppressed
MirtazapineMirtazapine14suppressed
Pramipexole DihydrochloridePramipexole Di-Hcl14suppressed
RizatriptanRizatriptan Benzoate14suppressed
Ropinirole HclRopinirole Hcl14suppressed
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14suppressed
EzetimibeEzetimibe13suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13suppressed
Glipizide ErGlipizide13suppressed
OzempicSemaglutide13suppressed
XanaxAlprazolam13suppressed
Diltiazem 24hr ErDiltiazem Hcl12suppressed
FenofibrateFenofibrate12suppressed
GlimepirideGlimepiride12suppressed
Clonidine HclClonidine Hcl11suppressed
LamotrigineLamotrigine11suppressed
Propranolol HclPropranolol Hcl11suppressed
Spiriva HandihalerTiotropium Bromide11suppressed
TelmisartanTelmisartan11suppressed
TestosteroneTestosterone11suppressed
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $51.55 · 1 records HEARTFLOW, INC. FFRct
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error